Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

BackgroundWe previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumor burden for starting lenvatinib still remains to...

Full description

Bibliographic Details
Main Authors: Chiaki Suzuki, Naomi Kiyota, Yoshinori Imamura, Hideaki Goto, Hirotaka Suto, Naoko Chayahara, Masanori Toyoda, Yasuhiro Ito, Akihiro Miya, Akira Miyauchi, Masanori Teshima, Naoki Otsuki, Ken-ichi Nibu, Hironobu Minami
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
radioiodine-refractory differentiated thyroid cancer (RR-DTC)
multi-target kinase inhibitors (mTKIs)
lenvatinib
long-term responders
maximum shrinkage of tumor burden
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.638123/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.638123/full

Similar Items